Dai Jinhua¹, Ma Jianbo¹, Yu Bixia², Zhu Zhankun¹, Hu Yanqin²

Oncology Research, Vol.27, No.1, pp. 107-115, 2019, DOI:10.3727/096504018X15205622257163

Abstract THIS ARTICLE WAS WITHDRAWN BY THE PUBLISHERS IN OCTOBER 2020. More >

Qin Liu^*†, Wei Wang^†, Fangqiong Li^†, Dongyang Yu^‡, Chunfen Xu^*, Hongbing Hu^*

Oncology Research, Vol.27, No.9, pp. 1043-1050, 2019, DOI:10.3727/096504019X15560124931900

Abstract Triptolide, an extract of Tripterygium wilfordii, has been shown to have a potent anticancer activity. In the present study, it was found that triptolide could effectively induce apoptosis and inhibit proliferation and invasion in malignant MDA-MB-231 breast cancer cells. The study focused on its effect on inhibiting invasion, which has not been extensively reported to date. We predicted that triptolide may change invasion activity via microRNAs (miRNAs), which have been recognized as important regulators of gene expression. miRNAome variation in MDA-MB-231 cells with or without triptolide treatment demonstrated that miR-146a was upregulated following treatment with triptolide. Our previous studies have… More >

Ji SHI; Peixin SUN, Ye ZHANG, Bing YAO, Haozhe PIAO

BIOCELL, Vol.43, No.3, pp. 119-128, 2019, DOI:10.32604/biocell.2019.07577

Abstract Glioma is the most common primary malignant brain tumor with a poor survival rate. In recent years, no significant progress has been made in the treatment of gliomas in contrast to the development of improved diagnosis via molecular typing. Newcastle disease virus (NDV), a negative-stranded RNA virus that exhibits oncolytic activity, has been investigated for its capacity to elicit antitumor activity in many types of cancers, including glioma. Therefore, application of oncolytic viruses, such as NDV, as a new treatment strategy to specifically target aberrant signaling in glioblastomas has brought new hope. For many years, NDV has been investigated for… More >